Menu Menu


AZN Financials       Clear


AZN        0000901832    
Filing Date Form Type Description Document
2020-10-28 6-K ENHERTU GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF HER2-POSITIVE MET View Document
2020-10-28 6-K FORXIGA CARDIOVASCULAR OUTCOMES BENEFIT APPROVED IN CHINA View Document
2020-10-20 6-K TAGRISSO ADJUVANT LUNG CANCER US PRIORITY REVIEW View Document
2020-10-19 6-K FORXIGA HF RECEIVES POSITIVE CHMP OPINION View Document
2020-10-19 6-K TRIXEO AEROSPHERE RECEIVES POSITIVE CHMP OPINION View Document
2020-10-13 6-K COVID-19 ANTIBODIES ADVANCE AND GET US FUNDING View Document
2020-10-02 6-K FARXIGA GRANTED US BTD IN CHRONIC KIDNEY DISEASE View Document
2020-10-01 6-K TOTAL VOTING RIGHTS View Document
2020-09-25 6-K DIRECTORATE CHANGE View Document
2020-09-24 CERT View Document
2020-09-24 8-A12B 8-A12B View Document
2020-09-24 25 25 View Document
2020-09-21 6-K LYNPARZA RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR BRCA-MUTATED METASTATIC View Document
2020-09-21 6-K LYNPARZARECOMMENDED FOR APPROVAL IN EU BY CHMP AS 1ST-LINE MAINTENANCE TREATMENT View Document
2020-09-21 6-K TAGRISSO REDUCED THE RISK OF DISEASE RECURRENCE IN THE BRAIN BY 82% IN THE ADJUV View Document
2020-09-10 6-K ASTRAZENECA TO LIST US ADR EQUITY AND ALL US DEBT SECURITIES ON NASDAQ View Document
2020-09-10 6-K FASENRA MET BOTH CO-PRIMARY ENDPOINTS OF REDUCED NASAL POLYP SIZE AND BLOCKAGE I View Document
2020-09-01 6-K TOTAL VOTING RIGHTS View Document
2020-09-01 6-K IMFINZI APPROVED IN EU FOR SMALL CELL LUNG CANCER View Document
2020-09-01 6-K FARXIGA REDUCES CKD PROGRESSION AND RISK OF DEATH View Document
2020-08-25 6-K PHASE I CLINICAL TRIAL INITIATED FOR MONOCLONAL ANTIBODY COMBINATION FOR THE PRE View Document
2020-08-21 6-K IMFINZI APPROVED IN JAPAN FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG C View Document
2020-08-18 6-K IMFINZI GRANTED FDA PRIORITY REVIEW FOR LESS-FREQUENT, FIXED-DOSE USE View Document
2020-08-12 CERT NYSE CERTIFICATION View Document
2020-08-06 8-A12B FORM 8-A12B View Document
2020-08-06 6-K FORM 6-K View Document
2020-08-05 424B2 FORM 424B2 View Document
2020-08-04 6-K ASTRAZENECA PRICES A $3BN BOND ISSUE View Document
2020-08-04 FWP FORM FWP View Document
2020-08-03 S-8 S-8 View Document
2020-08-03 6-K TOTAL VOTING RIGHTS View Document
2020-08-03 FWP FORM FWP View Document
2020-08-03 424B2 FORM 424B2 View Document
2020-07-31 6-K/A 6-K/A View Document
2020-07-30 6-K AZN: H1 2020 RESULTS View Document
2020-07-30 6-K TAGRISSO US BTD FOR EGFRM ADJUVANT LUNG CANCER View Document
2020-07-29 6-K BOARD COMMITTEE CHANGES View Document
2020-07-28 6-K FARXIGA DAPA-CKD TRIAL MET ALL ENDPOINTS View Document
2020-07-27 6-K IMFINZI RECOMMENDED FOR EU APPROVAL IN SCLC View Document
2020-07-27 6-K CALQUENCE RECEIVES POSITIVE CHMP OPINION FOR CLL View Document
2020-07-27 6-K ASTRAZENECA ENTERS COLLABORATION IN ONCOLOGY View Document
2020-07-24 6-K BREZTRI AEROSPHERE APPROVED IN THE US FOR THE MAINTENANCE TREATMENT OF COPD View Document
2020-07-22 6-K HOLDING(S) IN COMPANY View Document
2020-07-22 6-K HOLDING(S) IN COMPANY View Document
2020-07-21 6-K HOLDING(S) IN COMPANY View Document
2020-07-21 6-K HOLDING(S) IN COMPANY View Document
2020-07-20 6-K COVID-19 VACCINE AZD1222 SHOWED ROBUST IMMUNE RESPONSES IN ALL PARTICIPANTS IN P View Document
2020-07-16 6-K DIRECTOR DECLARATION View Document
2020-07-09 6-K BRILINTA GRANTED US FDA PRIORITY REVIEW FOR STROKE View Document
2020-07-08 6-K LYNPARZA APPROVED IN THE EU FOR BRCA- MUTATED METASTATIC PANCREATIC CANCER View Document
2020-07-01 6-K TOTAL VOTING RIGHTS View Document
2020-06-30 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-06-30 6-K SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR NEUROFIBROMATOSIS TYPE View Document
2020-06-26 11-K View Document
2020-06-17 6-K HOLDING(S) IN COMPANY View Document
2020-06-17 6-K HOLDING(S) IN COMPANY View Document
2020-06-15 6-K ASTRAZENECA TO SUPPLY EUROPE WITH UP TO 400 MILLION DOSES OF OXFORD UNIVERSITY'S View Document
2020-06-11 6-K EMTN PROGRAMME ROUTINE TECHNICAL UPDATE: PUBLICATION OF PROSPECTUS View Document
2020-06-01 6-K TOTAL VOTING RIGHTS View Document
2020-06-01 6-K BLOCK LISTING INTERIM REVIEW View Document
2020-06-01 6-K LYNPARZA RECOMMENDED FOR APPROVAL IN EU BY CHMP FOR BRCA-MUTATED METASTATIC PANC View Document
2020-06-01 6-K BRILINTA APPROVED IN THE US TO REDUCE THE RISK OF A FIRST HEART ATTACK OR STROKE View Document
2020-05-29 6-K ENHERTUSIGNIFICANTLY IMPROVED TUMOUR RESPONSE RATE AND OVERALL SURVIVAL IN HER2- View Document
2020-05-29 6-K IMFINZI SHOWED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE View Document
2020-05-29 6-K TAGRISSO DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATM View Document
2020-05-26 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-05-22 6-K ENHERTU GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR GASTRIC CANCER View Document
2020-05-21 6-K ASTRAZENECA ADVANCES RESPONSE TO GLOBAL COVID-19 CHALLENGE AS IT RECEIVES FIRST View Document
2020-05-20 6-K LYNPARZA APPROVED IN THE US FOR HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT View Document
2020-05-18 6-K ENHERTU US BREAKTHROUGH STATUS FOR LUNG CANCER View Document
2020-05-18 6-K BEVESPI AEROSPHERE APPROVED IN CHINA FOR COPD View Document
2020-05-11 6-K ENHERTU GRANTED BREAKTHROUGH THERAPY DESIGNATION IN THE US FOR HER2-POSITIVE MET View Document
2020-05-11 6-K ASTRAZENECA RECOVERY OF GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN COM View Document
2020-05-11 6-K LYNPARZA APPROVED IN THE US AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F View Document
2020-05-06 6-K FARXIGA APPROVED IN THE US FOR THE TREATMENT OF HEART FAILURE IN PATIENTS WITH H View Document
2020-05-01 6-K TOTAL VOTING RIGHTS View Document
2020-04-29 6-K RESULT OF AGM View Document
2020-04-29 6-K AZN: FIRST-QUARTER 2020 RESULTS View Document
2020-04-24 6-K LYNPARZA DEMONSTRATED OVERALL SURVIVAL BENEFIT IN PHASE III PROFOUND TRIAL FOR B View Document
2020-04-17 6-K CHANGES TO ARRANGEMENTS FOR ANNUAL GENERAL MEETING View Document
2020-04-14 6-K KOSELUGO (SELUMETINIB) APPROVED IN US FOR PAEDIATRIC PATIENTS WITH NEUROFIBROMAT View Document
2020-04-14 6-K TAGRISSO PHASE III ADAURA TRIAL WILL BE UNBLINDED EARLY AFTER OVERWHELMING EFFIC View Document
2020-04-02 6-K ASTRAZENECA DIVESTMENT OF MOVANTIK TO REDHILL BIOPHARMA COMPLETED View Document
2020-04-01 6-K TOTAL VOTING RIGHTS View Document
2020-03-31 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-03-30 6-K FARXIGA PHASE III DAPA-CKD TRIAL WILL BE STOPPED EARLY AFTER OVERWHELMING EFFICA View Document
2020-03-30 6-K IMFINZI APPROVED IN THE US FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER View Document
2020-03-26 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-03-26 6-K LOKELMA APPROVED IN JAPAN FOR THE TREATMENT OF HYPERKALAEMIA View Document
2020-03-20 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-03-19 6-K LYNPARZA GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR BRCA-MUTATED METASTATIC PA View Document
2020-03-17 6-K IMFINZI CONFIRMED A SUSTAINED OVERALL SURVIVAL BENEFIT IN FINAL ANALYSIS OF THE View Document
2020-03-12 6-K 6-K View Document
2020-03-12 6-K NOTICE OF AGM View Document
2020-03-12 6-K UPDATE ON PHASE III GY004 TRIAL FOR CEDIRANIB ADDED TO LYNPARZA IN PLATINUM-SENS View Document
2020-03-10 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-03-06 6-K UPDATE ON PHASE III DANUBE TRIAL FOR IMFINZI AND TREMELIMUMAB IN UNRESECTABLE, S View Document
2020-03-04 6-K FILING OF FORM 20-F WITH SEC View Document
2020-03-03 IRANNOTICE IRANNOTICE View Document
2020-03-03 20-F 20-F View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

(402) 804-8299